(Date:5/17/2013)... Calif. , May 17, 2013 Cellular ... has achieved 50% enrollment of the total projected ... evaluate the safety and preliminary efficacy of the ... therapy for Knee Osteoarthritis (KOA). To date the ... reported. The Phase I open label ...
(Date:5/17/2013)... May 17, 2013 Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy. The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board. In this study, INS001 ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3... 2008 RiverVest Venture Partners,announced today that it ... Fund II, L.P., with total committed capital of ... was licensed,as a Small Business Investment Company, had ... of leverage from the Small Business Administration., ...
... and JERSEY CITY, New Jersey, April 11, Rosetta ... development of microRNA-based diagnostics and therapeutics, announced,today it ... AACR,conference in San Diego. The posters will include ... they may be applied to develop,objective and standardized ...
... 2008 In the event of an outbreak or ... responsible for virulence or drug resistance is essential to ... analysis of a pathogen genome is time-intensive and likely ... developed a comparative genomics strategy to drastically reduce the ...
Cached Biology Technology:RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing 2Phospho-Cyclin D1 (Thr286) Antibody...
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Lipid Phosphate Phosphohydrolase 2...
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Biology Products:Biology NavigationMedical Navigation